Publication | Closed Access

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolRandomised Phase 3HematologyPharmacologyPharmacotherapyMedicineAplastic AnemiaJak InhibitorMyeloid Neoplasia